Document:

ex_236118.htm

EXHIBIT 10.29

 

[*] Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.  

Amendment No. 1 to

Patent and Technology License Agreement

 

This Amendment No. 1 to Patent and Technology License Agreement (“Amendment No. 1”) is effective as of the date of the last authorized signature affixed hereto (the “Amendment No. 1 Date”) and is made by and among The Board of Regents (“Board”) of The University of Texas System (“System”), on behalf of The University of Texas M. D. Anderson Cancer Center (“MD Anderson”), a member institution of System, and Genprex, Inc., having a place of business at Dell Medical School, Health Discovery Building, 1601 Trinity Street, Bldg. B #3.312.09, Austin, Texas 78712 (“Licensee”).  Capitalized terms used in this Amendment No. 1 and not otherwise defined herein shall have the meanings set forth in the Original Agreement (as defined below).

 

Recitals

 

	 	
			A.

				
			Licensee and Board entered into that certain Patent and Technology License Agreement dated May 4th, 2020 (the “Original Agreement”).

			

 

	 	
			B.

				
			Licensee and Board desire to add technology and patent rights related to MD Anderson’s Information Disclosure Report MDA11-043 to the Licensed Subject Matter of the Original Agreement.

			

 

Accordingly, in consideration of the mutual covenants contained herein, the sufficiency of which is hereby acknowledged, Licensee and Board, on behalf of MD Anderson, hereby agree to the following:

 

	 	
			I.

				
			Amendments 

			

 

	 	
			1.

				
			Section 2.24 of the Original Agreement is deleted and replaced with new Section 2.24 as follows:

			

 

“2.24   Sale or Sold means the transfer or disposition of a Licensed Product for value; provided, however, that a transfer or disposition of a Licensed Product for value shall not be included in Sales if (a) the transfer is to Licensee or a Sublicensee that does not acquire such Licensed Product for end use or (b) the transfer is to a Royalty Free Practitioner.  As used herein, “Royalty-Free Practitioner” means MD Anderson and the following individuals: Jack A. Roth, M.D., David Stewart, M.D.; Charles Lu, M.D.; and Ignacio I. Wistuba, M.D.  (“Practitioner Inventors”), and any partner or associate who practices medicine with one or more of the Practitioner Inventors, but with respect to such partner or associate, only for such time as he/she is engaged in a bona fide medical practice with one or more of the Practitioner Inventors.”

 

	 	
			2.

				
			New Section 2.30 is added to Article II of  the Original Agreement as follows:

			

 

“2.30.  MDA11-043 Valid Claim means a Valid Claim of any Patent Right claiming technology described in MDA11-043.”

 

 

 

 

	 	
			3.

				
			New Section 3.5 is added to Article III of the Original Agreement as follows:

			

 

“Notwithstanding anything to the contrary in this Agreement, with respect to subject matter described in MDA11-043, the grant of Section 3.1 is subject to any encumbrance arising or resulting from research support or funding under either of the following: (a) the Commonwealth Phase I Study grant for the project titled “Commonwealth Phase I Study” (MDA Acct. number 894464) and the Helen & Jin Ryu Fund for Gene Therapy grant for the project titled “Gene Therapy for Lung Cancer” (MDA Acct. No. 812206).” 

 

	 	
			4.

				
			Section 4.1(c) of the Original Agreement is deleted in its entirety and replaced with the following new Section 4.1(c):

			

 

“4.1(c) Annual Maintenance Fees.  Nonrefundable annual license maintenance fees (“Annual Maintenance Fees”) as follows:

 

	 	
			i.

				
			$[*], escalating by $[*] per year, until First Sale; provided, however, in no event shall an Annual Maintenance Fee exceed $[*].  By way of clarification and not by limitation, the Annual Maintenance Fee due for the second, third, fourth etc. anniversaries of the Agreement shall be $[*], $[*], $[*], etc., up to a maximum of $[*].”

			

 

The Annual Maintenance Fees will not reduce the amount of any other payment provided for in this Article IV.  The Annual Maintenance Fees will be payable within thirty (30) calendar days of each anniversary of the Effective Date.

 

	 	
			5.

				
			To add a Milestone Event,  Section 4.1(f) of the Original Agreement is deleted in its entirety and replaced with the following new Section 4.1(f):

			

 

(f)        The following Milestone Payments are payable for each occurrence of each Milestone Event as set forth in Table 4.1(f), regardless of whether the milestone is achieved by Licensee, a Sublicensee or Affiliate:

 

	
			Table 4.1(f)

			
	
			Milestone Event

				
			Milestone Payment

			
	
			1. [*]

				
			[*] Dollars ($[*])

			
	
			2. [*]

				
			[*] Dollars ($[*])

			
	
			3. [*]

				
			[*] Dollars ($[*])

			
	
			4. [*]

				
			[*] Dollars ($[*])

			
	
			5. [*]

				
			[*] Dollars ($[*])

			
	
			6. [*]

				
			[*]Dollars ($[*])

			

 

For clarity, Milestone Event No. 5 shall be payable if the jurisdiction of the second Regulatory Approval of the Licensed Product is the same as, or different from, the jurisdiction of the first Regulatory Approval of such Licensed Product.  Milestone Payments related to the foregoing Milestone Events are payable one-time on a Licensed Product-by-Licensed Product basis.

 

 

 

 

	 	
			6.

				
			Section 14.2 of the Original Agreement is modified to update Licensee’s address for receipt of notices as follows:

			

 

Genprex, Inc.

3300 Bee Cave Road

Suite 650-227

Austin, TX 78746

 

The remainder of Section 14.2 remains unchanged.

 

	 	
			7.

				
			Exhibit A of the Original Agreement is deleted in its entirety and replaced with the following new Exhibit A:

			

 

EXHIBIT I

 

	
			MD Anderson Invention Disclosure Report (“IDR”) Number

				
			Inventors/Creators

				
			IDR Title

				
			U.S. and foreign (outside U.S.)

			patent applications/patent numbers

			
	
			[*]

				
			[*]

				
			[*]

				
			[*]

			
	
			[*]

				
			[*]

				
			[*]

				
			See list in row below:

			
	
			[*]

			

 

	 	
			II.

				
			Consideration 

			

	 	
			1.

				
			In consideration of rights granted by Board to Licensee under this Amendment No. 1 and in addition to the additional consideration provided in new Sections 4.1(c) and 4.1(f), Licensee agrees to pay MD Anderson each of the following:

			

 

	 	
			a.

				
			Patent Expenses: All unreimbursed Patent Expenses related to patents and patent application for subject matter described in MDA11-043 prior to or after the Effective Date for so long as  the Original Agreement remains in effect.  MD Anderson will invoice Licensee after this Amendment No. 1 has been fully executed by all Parties for such unreimbursed Patent Expenses incurred as of as of the Amendment No. 1 Date and on a quarterly basis thereafter as provided in the Original Agreement.  The invoiced amounts will be due and payable by Licensee within thirty (30) calendar days of invoice.

			

 

	 	
			b.

				
			Amendment Fee. As a condition precedent to the inclusion of rights related to MDA11-043 as Licensed Subject Matter in the Original Agreement, a nonrefundable amendment fee in the amount of $[*] (“Amendment Fee”).  This upfront licensee fee will not reduce the amount of any other payment provided for in the Original Agreement, and is due and payable not later than thirty (30) calendar days after the Amendment No. 1 Date.  The obligation to timely pay the Amendment Fee is not subject to any cure period.

			

 

	 	
			III.

				
			General

			

	 	
			1.

				
			Licensee and Board, on behalf of MD Anderson, acknowledge and agree that, except as set forth in this Amendment No. 1, the terms and conditions of the Original Agreement shall remain in full force and effect on a going forward basis.

			

 

[Signatures appear on the following page]

 

 

 

IN WITNESS WHEREOF, the parties hereto have caused their duly authorized representatives to execute this Amendment No. 1.

 

 

	
			BOARD OF REGENTS OF THE

			UNIVERSITY OF TEXAS SYSTEM,

			on behalf of

			THE UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER

			By /s/ Ben Melson____________________

			 Ben Melson

			      Senior Vice President,

			 Chief Financial Officer

			 The University of Texas

			 M. D. Anderson Cancer Center

			Date: March 3, 2021

				
			GENPREX, INC.

			By /s/ Rodney Varner __________________

			Printed Name: Rodney Varner

			Title: President & Chief Executive Officer

			Date: March 3, 2021

			
	 	 
	
			Approved as to Content:

			By /s/ Ferran Prat_____________________

			   Ferran Prat, J.D., Ph.D.

			 Senior Vice President, Research

			 Administration & Industry Relations                             

			 M. D. Anderson Cancer Center

			Date: March 3, 2021EX-10.8

 Exhibit 10.8 
  

 
 February 6, 2014 

Kathy Hibbs 

                     

                     

Dear Kathy: 
 23andMe, Inc. (the
“Company”) is pleased to offer to you employment on the following terms: 
 1.
Position. Your initial title will be Chief Legal and Regulatory Affairs Officer, and you will report to Andy Page, the Company’s President. This is a full-time exempt position. 

2. Base Salary. Subject to adjustment pursuant to the Company’s employment compensation policies as
in effect and revised from time to time, you will be paid a base salary at an annualized rate of $400,000, payable in accordance with the Company’s standard payroll schedule, which is currently semi-monthly. 

3. Employee Benefits. As a regular employee of the Company, you will be eligible to participate in a
number of Company-sponsored benefit plans. The Company reserves the right to modify, change, or discontinue all or part of these benefits at any time at its sole discretion. 

4. Stock Option. The Company will recommend to the Company’s Board of Directors (the
“Board”) that you be granted an option to purchase up to 525,000 shares of the Company’s Common Stock (the “Option”)’. The grant of the Option is subject to the Board’s approval and the
promise to recommend such approval is not a promise of compensation and is not intended to create any obligation on the part of the Company. If approved, the exercise price per share of the Option will be equal to the price determined by the Board
per share on the date the Option is granted. The Option will be subject to the terms and conditions applicable to options granted under the Company’s 2006 Equity Incentive Plan (as amended) (the “Plan”), as described in
the Plan and the applicable Stock Option Agreement (as defined in the Plan). You will vest and become exercisable in twenty-five percent (25%) of the Option shares after twelve (12) months of continuous service, and the balance will vest and
become exercisable in equal monthly installments over the next thirty-six (36) months of continuous service, as described in the applicable Stock Option Agreement. 

5. Incentive Bonus. In addition, you will be eligible to be considered for an incentive bonus for each fiscal year,
commencing with the Company’s 2014 fiscal year. The bonus (if any) will be awarded based on objective or subjective criteria established by you and the Company’s President and approved by the Board. Your target bonus amount for each fiscal
year will be equal to thirty percent (30%) of your then annual base salary, provided that with respect to the Company’s 2014 fiscal year, you will be guaranteed an incentive bonus of no less than $90,000, provided that you commence employment
by no later than April 1, 2014 and, if you remain in employment with the Company until the payment date of the 2014 incentive bonus. 

 Kathy Hibbs 
 
Page
 2
 
  

 The incentive bonus for each fiscal year will be paid after the Company’s books for that
year have been closed and will be paid only if you are employed by the Company at the time of payment. In no event will a bonus be paid later than March 15 of the year following the year in which the bonus was earned. The determinations of the
Board with respect to each of your incentive bonuses will be final and binding. 
 6. Change in Control Severance
Benefits. If you experience a Qualifying Termination (as defined below), provided that you satisfy the Conditions (as defined below) within the Deadline (as defined below), then (a) the Company will pay you severance pay for a
period of six (6) months at your monthly base salary rate that was in effect at the time of the Qualifying Termination and (b) fifty percent (50%) of your then unvested Option shares will become fully vested and exercisable. Such severance
pay will be paid in accordance with the Company’s standard payroll schedule on the Company’s payroll dates at your regular payroll rate immediately prior to the Qualifying Termination, commencing on the Company’s first regular payroll
date following the last day of the Deadline, and will be subject to all applicable withholdings. Notwithstanding anything stated herein to the contrary, the severance provided in connection with your Qualifying Termination under this section is
intended to be exempt from Internal Revenue Code Section 409A pursuant to Treasury Regulation Section 1.409A-1 (b)(9)(iii) and to the extent it is exempt pursuant to such section it will in any event
be paid no later than the last day of your second taxable year following the taxable year in which your Qualifying Termination has occurred. 

To receive any of the severance pay or vesting acceleration described in this Section 6 or Section 7 below, (i) you must execute
(and not revoke) a full and complete general release of all claims in a form provided by the Company without alteration and (ii) you must have returned all Company property (collectively, (i) and (ii) are the
“Conditions”), in each case by the forty-fifth (45th) day (the “Deadline”) after your Qualifying Termination. 

For the purposes of this offer letter only, you will be deemed to have incurred a “Qualifying Termination” if you are
subject to an “Involuntary Termination” (as defined in this Section) that occurs in connection with or within twelve (12) months following a Change in Control (as defined in this Section). 

For purposes of this Agreement: 

(a) a “Change in Control” means a (i) consolidation, reorganization or merger of the Company with
or into any other entity or entities in which the holders of the Company’s outstanding shares immediately before such consolidation, reorganization or merger do not, immediately after such consolidation, reorganization or merger, retain stock
or other ownership interests representing a majority of the voting power of the surviving entity or entities as a result of their shareholdings in the Company immediately before such consolidation, reorganization or merger; or (ii) a sale or
all or substantially all of the Company’s assets that is followed by a distribution of the proceeds to the Company’s stockholders. 

(b) an “Involuntary Termination” means an involuntary separation from service, as defined in Treasury
Regulation l.409A-l(n), (i) by the Company for any reason other than (A) Cause, as defined below, (B) death or (C) Permanent Disability, as defined below or (ii) by you for Good Reason (as
defined below). 

 Kathy Hibbs 
 
Page
 3
 
  

 (c) “Cause” means (i) any willful, material
violation by you of any law or regulation applicable to the business of the Company, your conviction for, or guilty plea to, a felony or a crime involving moral turpitude, or any willful perpetration by you of a common law fraud, (ii) your
commission of an act of personal dishonesty which involves personal profit in connection with the Company or any other entity having a business relationship with the Company, (iii) any material breach by you of any provision of any agreement or
understanding between the Company and you regarding the terms of your service as an employee, officer, director or consultant to the Company, including without limitation, your willful and continued failure or refusal to perform the material duties
required of you as an employee, officer, director or consultant of the Company, other than as a result of having a disability, or a breach of any applicable invention assignment and confidentiality agreement or any agreement between the Company and
you, (iv) your disregard of the policies of the Company so as to cause loss, damage or injury to the property, reputation or employees of the Company, (v) your violation or failure to comply with any of the Company’s confidential
information, privacy or similar policy or program or (vi) any other misconduct by you which is materially injurious to the financial condition or business reputation of, or is otherwise materially injurious to, the Company. 

(d) “Good Reason” means, without your express written consent, the occurrence of any one or more of
the following: (i) a change in your position with the Company that materially reduces your level of authorities, responsibilities or duties (provided that such reduction would not include remaining in the same relative position of
responsibility within the Company following a Change in Control even if the Company were a subsidiary of another entity); (ii) a reduction in your base salary by more than ten percent (10%) unless (A) you consent thereto in your discretion, or
(B) the annual salaries of all Company employees are similarly reduced; or (iii) receipt of notice that your principal workplace will be relocated to increase your commute by more than fifty (50) miles. The conditions set forth in
this paragraph will be considered “Good Reason” only if (i) you give the Company written notice of one of the conditions described in this paragraph within thirty (30) days after the condition comes into existence; (ii) the
Company fails to remedy the condition within thirty (30) days after receiving your written notice; and (iii) after the Company’s failure to remedy the condition within the previously described
30-day period, you resign from the Company within ninety (90) days after one of the above conditions has come into existence without your consent. 

(e) “Permanent Disability” means that you are unable to perform the essential functions of your
position, with or without reasonable accommodation, for a period of at least 120 consecutive days because of a physical or mental impairment. 

7. Severance Benefits Prior to a Change in Control. For purposes of clarity, nothing in this Section 7 will
be duplicative with the payments and benefits set forth in Section 6 in connection with a Change in Control. If you are subject to an involuntary separation from service, as defined in Treasury Regulation
1.409A-l(n), by the Company for any reason other than (i) Cause, (ii) death or (iii) Permanent Disability (a “Separation from Service”), that occurs prior to a Change in Control,
provided that you satisfy the Conditions within the Deadline, then the Company will pay you cash severance equal to four (4) months of your base salary at the rate then in effect. Your cash severance will be paid in accordance with the
Company’s standard payroll schedule on the Company’s payroll dates at your regular payroll rate immediately prior to the Separation from Service, commencing on the Company’s first regular payroll date following the last day of the
Deadline, and will be subject to all applicable withholdings. Notwithstanding anything stated herein to the contrary, the severance provided in connection with your Separation from Service under this section is intended to be exempt from Internal
Revenue Code Section 409A pursuant to Treasury Regulation Section 1.409A- 1 (b)(9)(iii) and to the extent it is exempt pursuant to such section it will in any event be paid no later than the last day of your second taxable year following
the taxable year in which your Separation from Service has occurred. 

 Kathy Hibbs 
 
Page
 4
 
  

 8. Code Section 409A.
Notwithstanding the above, if any of the salary continuation payments provided in connection with your Qualifying Termination or Separation from Service does not qualify for any reason to be exempt from Internal Revenue Code
(“Code”) Section 409A and you are deemed by the Company at the time of your Qualifying Termination or Separation from Service to be a “specified employee,” as defined in Code
Section 409A (i.e. a key employee of a publicly traded company), each such salary continuation payment will not be made or commence until the date which is the first (1st) business day of the seventh (7th) month after your Qualifying
Termination or Separation from Service and the installments that otherwise would have been paid during the first six (6) months after your Qualifying Termination or Separation from Service will be paid in a lump sum on the first (1st) business
day of the seventh (7th) month after your Qualifying Termination or Separation from Service, with the remaining payments (if any) to be made in accordance with the applicable schedule set forth above. Such deferral will only be effected to the
extent required to avoid adverse tax treatment to you, including (without limitation) the additional twenty percent (20%) federal tax for which you would otherwise be liable under Section 409A(a)(1)(B) of the Code in the absence of such
deferral. 
 9. Invention Assignment and Confidentiality Agreement. To protect the interests of the
Company, like all Company employees, you will be required to sign the Company’s standard Employee Invention Assignment and Confidentiality Agreement (the “Confidentiality Agreement”) as a condition of your employment
with the Company. A copy of this agreement is attached as Exhibit A. Please note this agreement contains many very important provisions, including (without limitation) those that require the assignment of inventions, disclosure of inventions,
obligations of confidentiality, non-competition, non-solicitation, and rights to use your name and likeness, etc. Please review the agreement carefully. 

10. At-Will Employment. Employment with the Company is for no specific
period of time. You understand that your employment with the Company will be “at-will,” which means that either you or the Company may terminate your employment at any time and for any or no reason,
with or without prior notice and with or without Cause. Although your job duties, title, compensation and benefits, as well as the Company’s personnel policies and procedures, may change from time to time, the
“at-will” nature of your employment may only be changed in an express written agreement signed by you and the President of the Company. 

11. Proof of Authorization to Work in the United States. Please note that because of employer regulations
adopted in the Immigration Reform and Control Act of 1986, your employment with the Company is contingent upon your providing legal proof of your identity and authorization to work in the United States. Attached as Exhibit B is the I-9 document that you will be required to complete and return on or before your first day of employment. Please refer to this document and bring the correct identification with you. Failure to provide proper
identification may delay placement on payroll and ultimately result in mandatory termination. 
 12.
Representations. You represent and warrant that the credentials and information you provided to the Company related to your qualifications and ability to perform this position are true and correct. 

 Kathy Hibbs 
 
Page
 5
 
  

 13. Arbitration. Except as provided below, but excluding
claims for workers’ compensation, unemployment insurance claims, claims regarding proprietary information, trade secrets, assignment of intellectual property or claims under the Confidentiality Agreement, you and the Company agree to submit to
mandatory binding arbitration any dispute, claim or controversy arising out of, related to or connected with your employment by the Company or the termination of such employment, including, but not limited to, claims against any current or former
employee, director or agent of the Company, claims of discrimination, harassment, unpaid wages, breach of contract (express or implied), breach of the covenant of good faith and fair dealing, defamation, invasion of privacy, fraud,
misrepresentation, constructive discharge, wrongful termination or failure to provide a leave of absence, retaliation, torts, or claims regarding commissions, stock options or bonuses, infliction of emotional distress or unfair business practices,
as well as claims based upon any federal, state or local ordinance, statute, regulation or constitutional provision and any and all state or local laws prohibiting discrimination or regulating any terms or conditions of employment (collectively.
“Arbitrable Claims”). 
 The parties agree to submit any and all Arbitrable Claims to the American
Arbitration Association (AAA”) for final and binding arbitration by a single arbitrator in accordance with the AAA’s Employment Arbitration Rules and Mediation Procedures then in effect. Arbitration with the AAA shall be initiated as
provided for by the AAA Rules. The arbitrator’s decision must be written and must include the findings of fact and conclusions of law that support the decision. The arbitrator’s decision will be final and binding on both parties, except to
the extent applicable law allows for judicial review of arbitration awards. The arbitrator may award remedies that would otherwise be available to the parties if they were to bring the dispute in court. All arbitration hearings shall be conducted in
Santa Clara County, California. Arbitration shall be the exclusive method by which to resolve all Arbitrable Claims, except that each party may, at its or his/her option, seek injunctive relief in a court of competent jurisdiction together
with all rights of appeal related thereto, concerning any claim or claims related to the improper use, disclosure or misappropriation of a party’s proprietary, confidential or trade secret information. If any party opts out of arbitration for
the relief as provided in the preceding sentence the arbitrator shall have no jurisdiction to hear or determine any such claim. 

You and the Company will share the costs of arbitration equally, except that the Company will bear the cost of the
arbitrator’s fee and any other type of expense or cost that you would not be required to bear if you were to bring the dispute or claim in court. You will be responsible for your own attorney’s fees and the Company will be responsible for
its attorney’s fees, and the arbitrator may not award attorneys’ fees unless a statute or contract at issue specifically authorizes such an award. If an arbitrator or court of competent jurisdiction determines any provision of this
arbitration provision is illegal or unenforceable, then the arbitrator or court, as applicable, shall modify or replace the language of this arbitration provision with a valid and enforceable provision, but only to the minimum extent necessary to
render this arbitration provision legal and enforceable. 
 14. Company Policies. You agree to abide by all
applicable Company policies disclosed to you from time to time during the term of your employment. 
 15. Tax Matters
and Tax Advice. All forms of compensation referred to in this letter agreement are subject to reduction to reflect applicable withholding and payroll taxes and other deductions required by law. You are encouraged to obtain your own
tax advice regarding your compensation from the Company. You agree that the Company does not have a duty to design its compensation policies in a manner that minimizes your tax liabilities, and you will not make any claim against the Company or its
Board of Directors related to tax liabilities arising from your compensation, including any option granted to you. 

 Kathy Hibbs 
 
Page
 6
 
  

 16. Interpretation, Amendment and Enforcement. This
offer letter agreement and Exhibit A constitute the complete agreement between you and the Company, contain all of the terms of your employment with the Company and supersede any prior or contemporaneous agreements, representations or understandings
(whether written, oral or implied) between you and the Company. This letter agreement may not be amended or modified, except by an express written agreement signed by both you and a duly authorized officer of the Company. The terms of this letter
agreement and the resolution of any disputes as to the meaning, effect, performance or validity of this letter agreement or of any issues arising out of, related to, or in any way connected with, this letter agreement, your employment with the
Company or any other relationship between you and the Company (the “ Disputes’’) will be governed by this letter agreement and California law, excluding, however, laws relating to conflicts or choice of law. You and the
Company submit to the exclusive personal jurisdiction of the federal and state courts located in Santa Clara County, California in connection with any Dispute or any claim related to any Dispute and to the jurisdiction of the AAA in Santa Clara
County, California in connection with any Arbitrable Claims. 

 Kathy Hibbs 
 
Page
 7
 
  

 17. Acceptance. If you decide to accept our offer
of employment, and we hope that you will, please sign and date the enclosed copy of this letter agreement in the space indicated and return it to us. You will also be required to sign and complete the Company’s standard employment application
form. This offer may be withdrawn at any time prior to our receipt of your written acceptance and is contingent upon satisfactory completion of routine background and reference checks, your written acceptance by March 3, 2014, and your starting
work with the Company on or before April I, 2014. Please indicate your acceptance of this offer by signing this letter agreement and returning it to Kris Franco, Human Resources. You will also be asked to complete the attached 1-9 form on your first day of employment and sign the Employee Invention Assignment and Confidentiality Agreement and return one copy with the letter agreement. 

We look forward to the opportunity to welcome you to the Company. 

 

	
	Very truly yours,
	
	 /s/ Andrew Page

	Andrew Page
	President

 I have read and understood this letter agreement and hereby acknowledge, accept and agree to the terms as set forth
above and further acknowledge that no other commitments were made to me as part of my employment offer except as specifically set forth herein. 
  

	
	 /s/ Kathy Hibbs

	
	Signature of Kathy Hibbs
	
	Date signed: 3/11/2014
	
	Start Date:                             

 Exhibits; Enclosures: 

Exhibit A-Employee Invention Assignment and Confidentiality Agreement 

Exhibit B- I-9 Form 

Exhibit C- Background Check Authorization Forms

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00325-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00325-of-00352.parquet"}]]